Interleukin-1 Receptor Antagonists, Compositions, And Methods Of Treatment

Abstract

Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.


Claims
Download PDF
Document Preview
Document History
  • Publication: Dec 31, 2013
  • Application: May 5, 2005
    US US 12298905 A
  • Priority: May 5, 2005
    US US 12298905 A
  • Priority: May 5, 2004
    US US 71451204 P

Download Citation


Sign in to the Lens

Feedback